Eptifibatide: Difference between revisions
| Line 9: | Line 9: | ||
==Overview== | ==Overview== | ||
'''Eptifibatide''' ('''Integrilin''', [[Millennium Pharmaceuticals]], also co-promoted by Schering-Plough/Essex), is an [[antiplatelet drug]] of the [[glycoprotein IIb/IIIa inhibitor]] class.<ref name="Gribble2010">{{cite book|author=Gordon W. Gribble|title=Heterocyclic Scaffolds II: Indoles: Synthesis, Properties and Applications|url=http://books.google.com/books?id=srxzzUskq4wC&pg=PA11|accessdate=12 November 2010|date=15 December 2010|publisher=Springer|isbn=978-3-642-15732-5|pages=11–}}</ref> Eptifibatide is a [[cyclic compound|cyclic]] [[heptapeptide]] derived from a protein found in the venom of the southeastern pygmy rattlesnake (''[[Sistrurus miliarius barbouri]]''). It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short [[half-life]]. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody [[abciximab]] and the non-peptide [[tirofiban]] entered the global market. | |||
==Category== | ==Category== | ||
Revision as of 02:17, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Eptifibatide, click here
Synonyms / Brand Names: INTEGRILIN®
Overview
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Category
Cardiovascular Drugs:Antiplatelet drugs
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet.
References
- ↑ Gordon W. Gribble (15 December 2010). Heterocyclic Scaffolds II: Indoles: Synthesis, Properties and Applications. Springer. pp. 11–. ISBN 978-3-642-15732-5. Retrieved 12 November 2010.